A phase 1 study of OT-82.
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs OT-82 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 14 Dec 2017 New trial record
- 11 Dec 2017 According to a OncoTartis media release, the company received a round of finance from various investors to support this clinical trial.